Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0.00 | $19.1M |
| Operating income | -$13.5M | -$60.4M | -$106M | -$72.4M | -$58.6M | -$91.1M |
| Operating margin | — | — | — | — | — | -477.5% |
| Net income | -$68.4M | -$70.8M | -$101M | -$70.0M | -$49.8M | -$82.1M |
| Net margin | — | — | — | — | — | -430.3% |
| EPS (diluted) | -$29.93 | -$2.45 | -$1.84 | -$35.71 | -$2.34 | -$2.85 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$8.72M | -$52.9M | -$88.0M | -$60.4M | -$59.4M | -$69.2M |
| Capital expenditures | $1.54M | $5.74M | $6.59M | $30.0K | $468K | $827K |
| Free cash flow | -$10.3M | -$58.6M | -$94.6M | -$60.4M | -$59.9M | -$70.0M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $19.8M | $377M | $47.7M | $35.1M | $20.2M | $25.2M |
| Total assets | $22.6M | $402M | $322M | $70.4M | $215M | $306M |
| Total liabilities | $32.4M | $17.9M | $25.6M | $19.7M | $11.2M | $21.5M |
| Shareholders' equity | -$65.4M | $384M | -$24.2M | -$92.7M | $204M | $284M |
| Retained earnings | -$70.6M | -$141M | -$242M | -$95.2M | -$145M | -$227M |
| Shares (wtd avg diluted) | 10.3M | 28.9M | 54.9M | 1.96M | 21.3M | 28.8M |
Every figure is extracted from LENZ Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.